




PCT/EP200 4 / 0 1 4 4 3 6



INVESTOR IN PEOPLE




The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Anders Gernay*

Dated 30 November 2004

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road

Newport

South Wales NP10 8QQ

2200003-0060955-5 000245

P01/7700 0.00-0329498.0 ACCOUNT CHA

1. Your reference

4-33513P1

2. Patent application number

(The Patent Office will fill in this p

0329498.0

3. Full name, address and postcode of the or  
of each applicant  
(underline all surnames)

NOVARTIS AG  
LICHTSTRASSE 35  
4056 BASEL  
SWITZERLAND

Patent ADP number (if you know it)

If the applicant is a corporate body, give  
the country/state of its incorporation

SWITZERLAND

7125687005

4. Title of invention

Organic Compounds

5. Name of your agent (If you have one)

"Address for service" in the United  
Kingdom to which all correspondence  
should be sent  
(including the postcode)

Craig McLean

Novartis Pharmaceuticals UK Limited  
Patents and Trademarks  
Wimblehurst Road  
Horsham, West Sussex  
RH12 5AB  
07181522002✓

Patents ADP number (if you know it)

6. If you are declaring priority from one or  
more earlier patent applications, give  
the country and the date of filing of the  
or of each of these earlier applications  
and (if you know it) the or each application  
number

Country

Priority application number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise  
derived from an earlier UK  
application, give the number and the  
filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of  
right to grant of a patent required in  
support of this request? (Answer 'Yes' if:

Yes

a) any applicant named in part 3 is not an  
inventor, or

b) there is an inventor who is not named as  
an applicant, or

c) any named applicant is a corporate body.

(see note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 16

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)


Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application

Signature

Date



Craig McLean

19<sup>th</sup> December 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. Trevor Drew

01403 323069

## Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds


The present invention relates to a new use for a sphingosine-1-phosphate (S1P) receptor agonist, particularly in the treatment of brain degenerative diseases.

S1P receptor agonists are accelerating lymphocyte homing (LH) agents which elicit a lymphopenia resulting from a re-distribution, preferably reversible, of lymphocytes from circulation to secondary lymphatic tissue, without evoking a generalized immunosuppression. Naïve cells are sequestered; CD4 and CD8 T-cells and B-cells from the blood are stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP).

Furthermore, S1P receptor agonists are also compounds which signal as agonists at one or more sphingosine-1 phosphate receptors, e.g. S1P1 to S1P8. Agonist binding to a S1P receptor may e.g. result in dissociation of intracellular heterotrimeric G-proteins into  $G\alpha$ -GTP and  $G\beta\gamma$ -GTP, and/or increased phosphorylation of the agonist-occupied receptor and activation of downstream signaling pathways/kinases.

Examples of appropriate S1P receptor agonists are, for example:

- Compounds as disclosed in EP627406A1, e.g. a compound of formula I



wherein  $\text{R}_1$  is a straight- or branched ( $\text{C}_{12-22}$ )carbon chain

- which may have in the chain a bond or a hetero atom selected from a double bond, a triple bond, O, S,  $\text{NR}_6$ , wherein  $\text{R}_6$  is H, alkyl, aralkyl, acyl or alkoxycarbonyl, and carbonyl, and/or

- which may have as a substituent alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxyimino, hydroxy or carboxy; or

$\text{R}_1$  is

- a phenylalkyl wherein alkyl is a straight- or branched ( $\text{C}_{6-20}$ )carbon chain; or
- a phenylalkyl wherein alkyl is a straight- or branched ( $\text{C}_{1-30}$ )carbon chain wherein said phenylalkyl is substituted by
- a straight- or branched ( $\text{C}_{6-20}$ )carbon chain optionally substituted by halogen,

- a straight- or branched (C<sub>6-20</sub>)alkoxy chain optionally substituted by halogen,
- a straight- or branched (C<sub>6-20</sub>)alkenyloxy,
- phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl,
- cycloalkylalkyl substituted by C<sub>6-20</sub>alkyl,
- heteroarylalkyl substituted by C<sub>6-20</sub>alkyl,
- heterocyclic C<sub>6-20</sub>alkyl or
- heterocyclic alkyl substituted by C<sub>2-20</sub>alkyl,

and wherein


the alkyl moiety may have

- in the carbon chain, a bond or a heteroatom selected from a double bond, a triple bond, O, S, sulfinyl, sulfonyl, or NR<sub>6</sub>, wherein R<sub>6</sub> is as defined above, and
- as a substituent alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxy or carboxy, and

each of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, independently, is H, C<sub>1-4</sub> alkyl or acyl


or a pharmaceutically acceptable salt thereof;

- Compounds as disclosed in EP 1002792A1, e.g. a compound of formula II



wherein m is 1 to 9 and each of R'<sub>2</sub>, R'<sub>3</sub>, R'<sub>4</sub> and R'<sub>5</sub>, independently, is H, alkyl or acyl, or a pharmaceutically acceptable salt thereof;


- Compounds as disclosed in EP0778263 A1, e.g. a compound of formula III




wherein W is H; C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl or C<sub>2-6</sub>alkynyl; unsubstituted or by OH substituted phenyl; R''<sub>4</sub>O(CH<sub>2</sub>)<sub>n</sub>; or C<sub>1-6</sub>alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C<sub>3-8</sub>cycloalkyl, phenyl and phenyl substituted by OH;

X is H or unsubstituted or substituted straight chain alkyl having a number p of carbon atoms or unsubstituted or substituted straight chain alkoxy having a number (p-1) of carbon atoms, e.g. substituted by 1 to 3 substituents selected from the group consisting of C<sub>1-6</sub> alkyl, OH, C<sub>1-6</sub>alkoxy, acyloxy, amino, C<sub>1-6</sub>alkylamino, acylamino, oxo, haloC<sub>1-6</sub>alkyl, halogen, unsubstituted phenyl and phenyl substituted by 1 to 3 substituents selected from the group consisting of C<sub>1-6</sub>alkyl, OH, C<sub>1-6</sub>alkoxy, acyl, acyloxy, amino, C<sub>1-6</sub>alkylamino, acylamino, haloC<sub>1-6</sub>alkyl and halogen; Y is H, C<sub>1-6</sub>alkyl, OH, C<sub>1-6</sub>alkoxy, acyl, acyloxy, amino, C<sub>1-6</sub>alkylamino, acylamino, haloC<sub>1-6</sub>alkyl or halogen, Z<sub>2</sub> is a single bond or a straight chain alkylene having a number of carbon atoms of q, each of p and q, independently, is an integer of 1 to 20, with the proviso of 6 ≤ p+q ≤ 23, m' is 1, 2 or 3, n is 2 or 3, each of R''<sub>1</sub>, R''<sub>2</sub>, R''<sub>3</sub> and R''<sub>4</sub>, independently, is H, C<sub>1-4</sub>alkyl or acyl, or a pharmaceutically acceptable salt thereof,

- Compounds as disclosed in WO02/18395, e.g. a compound of formula IVa or IVb



or




wherein X<sub>a</sub> is O, S, NR<sub>1s</sub> or a group -(CH<sub>2</sub>)<sub>na</sub>-, which group is unsubstituted or substituted by 1 to 4 halogen; n<sub>a</sub> is 1 or 2, R<sub>1s</sub> is H or (C<sub>1-4</sub>)alkyl, which alkyl is unsubstituted or substituted by halogen; R<sub>1a</sub> is H, OH, (C<sub>1-4</sub>)alkyl or O(C<sub>1-4</sub>)alkyl wherein alkyl is unsubstituted or substituted by 1 to 3 halogen; R<sub>1b</sub> is H, OH or (C<sub>1-4</sub>)alkyl, wherein alkyl is unsubstituted or substituted by halogen; each R<sub>2a</sub> is independently selected from H or (C<sub>1-4</sub>)alkyl, which alkyl is unsubstituted or substituted by halogen; R<sub>3a</sub> is H, OH, halogen or O(C<sub>1-4</sub>)alkyl wherein alkyl is unsubstituted or substituted by halogen; and R<sub>3b</sub> is H, OH, halogen, (C<sub>1-4</sub>)alkyl wherein alkyl is unsubstituted or substituted by hydroxy, or O(C<sub>1-4</sub>)alkyl wherein alkyl is unsubstituted

or substituted by halogen;  $Y_a$  is  $-\text{CH}_2-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{CH}(\text{OH})-$ ,  $-\text{C}(\text{=NOH})-$ , O or S, and  $R_{4a}$  is  $(\text{C}_{4-14})$ alkyl or  $(\text{C}_{4-14})$ alkenyl;

or a pharmaceutically acceptable salt or hydrate thereof;

- Compounds as disclosed in WO 02/076995, e.g. a compound of formula V




wherein

$m_c$  is 1, 2 or 3;

$X_c$  is O or a direct bond;

$R_{1c}$  is H;  $\text{C}_{1-6}$  alkyl optionally substituted by OH, acyl, halogen,  $\text{C}_{3-10}$ cycloalkyl, phenyl or hydroxy-phenylene;  $\text{C}_{2-6}$ alkenyl;  $\text{C}_{2-6}$ alkynyl; or phenyl optionally substituted by OH;


$R_{2c}$  is



wherein  $R_{5c}$  is H or  $\text{C}_{1-4}$ alkyl optionally substituted by 1, 2 or 3 halogen atoms, and  $R_{6c}$  is H or  $\text{C}_{1-4}$ alkyl optionally substituted by halogen;

each of  $R_{3c}$  and  $R_{4c}$ , independently, is H,  $\text{C}_{1-4}$ alkyl optionally substituted by halogen, or acyl, and


$R_c$  is  $\text{C}_{13-20}$ alkyl which may optionally have in the chain an oxygen atom and which may optionally be substituted by nitro, halogen, amino, hydroxy or carboxy; or a residue of formula (a)



wherein  $R_{7c}$  is H,  $\text{C}_{1-4}$ alkyl or  $\text{C}_{1-4}$ alkoxy, and  $R_{8c}$  is substituted  $\text{C}_{1-20}$ alkanoyl, phenyl $\text{C}_{1-14}$ alkyl wherein the  $\text{C}_{1-14}$ alkyl is optionally substituted by halogen or OH, cycloalkyl $\text{C}_{1-14}$ alkoxy or phenyl $\text{C}_{1-14}$ alkoxy wherein the cycloalkyl or phenyl ring is optionally substituted by halogen,  $\text{C}_{1-4}$ alkyl and/or  $\text{C}_{1-4}$ alkoxy, phenyl $\text{C}_{1-14}$ alkoxy- $\text{C}_{1-14}$ alkyl, phenoxy $\text{C}_{1-14}$ alkoxy or phenoxy $\text{C}_{1-14}$ alkyl,



$R_c$  being also a residue of formula (a) wherein  $R_{8c}$  is  $C_{1-14}$ alkoxy when  $R_{1c}$  is  $C_{1-4}$ alkyl,  $C_{2-6}$ alkenyl or  $C_{2-6}$ alkynyl,  
or a compound of formula VI



wherein

$n_x$  is 2, 3 or 4

$R_{1x}$  is H;  $C_{1-6}$ alkyl optionally substituted by OH, acyl, halogen, cycloalkyl, phenyl or hydroxy-phenylene;  $C_{2-6}$ alkenyl;  $C_{2-6}$ alkynyl; or phenyl optionally substituted by OH;

$R_{2x}$  is H,  $C_{1-4}$  alkyl or acyl

each of  $R_{3x}$  and  $R_{4x}$ , independently is H,  $C_{1-4}$ alkyl optionally substituted by halogen or acyl,


$R_{5x}$  is H,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy, and

$R_{6x}$  is  $C_{1-20}$  alkanoyl substituted by cycloalkyl; cycloalkyl $C_{1-14}$ alkoxy wherein the cycloalkyl ring is optionally substituted by halogen,  $C_{1-4}$ alkyl and/or  $C_{1-4}$ alkoxy; phenyl $C_{1-14}$ alkoxy wherein the phenyl ring is optionally substituted by halogen,  $C_{1-4}$ alkyl and/or  $C_{1-4}$ alkoxy,

$R_{6x}$  being also  $C_{4-14}$ alkoxy when  $R_{1x}$  is  $C_{2-4}$ alkyl substituted by OH, or pentyloxy or hexyloxy when  $R_{1x}$  is  $C_{1-4}$ alkyl,


provided that  $R_{6x}$  is other than phenyl-butylenoxy when either  $R_{5x}$  is H or  $R_{1x}$  is methyl,  
or a pharmaceutically acceptable salt thereof;

- Compounds as disclosed in WO02/06268A1, e.g. a compound of formula VII



wherein each of  $R_{1d}$  and  $R_{2d}$ , independently, is H or an amino-protecting group;

$R_{3d}$  is hydrogen, a hydroxy-protecting group or a residue of formula



$R_{4d}$  is lower alkyl;

$n_d$  is an integer of 1 to 6;

$X_d$  is ethylene, vinylene, ethynylene, a group having a formula  $-D-CH_2-$  (wherein D is carbonyl,  $-CH(OH)-$ , O, S or N), aryl or aryl substituted by up to three substituents selected from group a as defined hereinafter;

$Y_d$  is single bond,  $C_{1-10}$ alkylene,  $C_{1-10}$ alkylene which is substituted by up to three substituents selected from groups a and b,  $C_{1-10}$ alkylene having O or S in the middle or end of the carbon chain, or  $C_{1-10}$ alkylene having O or S in the middle or end of the carbon chain which is substituted by up to three substituents selected from groups a and b;

$R_{5d}$  is hydrogen, cycloalkyl, aryl, heterocycle, cycloalkyl substituted by up to three substituents selected from groups a and b, aryl substituted by up to three substituents selected from groups a and b, or heterocycle substituted by up to three substituents selected from groups a and b;

each of  $R_{6d}$  and  $R_{7d}$ , independently, is H or a substituent selected from group a;


each of  $R_{8d}$  and  $R_{9d}$ , independently, is H or  $C_{1-4}$ alkyl optionally substituted by halogen;

<group a> is halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkylthio, carboxyl, lower alkoxy carbonyl, hydroxy, lower aliphatic acyl, amino, mono-lower alkylamino, di-lower alkylamino, lower aliphatic acylamino, cyano or nitro; and

<group b> is cycloalkyl, aryl, heterocycle, each being optionally substituted by up to three substituents selected from group a;


with the proviso that when  $R_{5d}$  is hydrogen,  $Y_d$  is either a single bond or linear  $C_{1-10}$ alkylene, or a pharmacologically acceptable salt or ester thereof;

-Compounds as disclosed in JP-14316985 (JP2002316985), e.g. a compound of formula VIII:




wherein  $R_{1e}, R_{2e}, R_{3e}, R_{4e}, R_{5e}, R_{6e}, R_{7e}, n_e, X_e$  and  $Y_e$  are as disclosed in JP-14316985; or a pharmacologically acceptable salt or ester thereof;

-Compounds as disclosed in WO 03/29184 and WO 03/29205, e.g. compounds of formula IX



wherein  $X_f$  is O or S, and  $R_{1f}$ ,  $R_{2f}$ ,  $R_{3f}$  and  $n_f$  are as disclosed in WO 03/29184 and O3/29205, each of  $R_{4f}$  and  $R_{5f}$ , independently is H or a residue of formula



wherein each of  $R_{8f}$  and  $R_{9f}$ , independently, is H or  $C_{1-4}$ alkyl optionally substituted by halogen; e.g. 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propane-diol or 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]propyl-1,3-propane-diol, or a pharmacological salt thereof.

In each case where citations of patent applications are given, the subject matter relating to the compounds is hereby incorporated into the present application by reference.


Acyl may be a residue  $R_y\text{-CO-}$  wherein  $R_y$  is  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl, phenyl or phenyl- $C_{1-4}$ alkyl. Unless otherwise stated, alkyl, alkoxy, alkenyl or alkynyl may be straight or branched.

When in the compounds of formula I the carbon chain as  $R_1$  is substituted, it is preferably substituted by halogen, nitro, amino, hydroxy or carboxy. When the carbon chain is interrupted by an optionally substituted phenylene, the carbon chain is preferably unsubstituted. When the phenylene moiety is substituted, it is preferably substituted by halogen, nitro, amino, methoxy, hydroxy or carboxy.

Preferred compounds of formula I are those wherein  $R_1$  is  $C_{13-20}$ alkyl, optionally substituted by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those wherein  $R_1$  is phenylalkyl substituted by  $C_{6-14}$ -alkyl chain optionally substituted by halogen and the alkyl moiety is a  $C_{1-6}$ alkyl optionally substituted by hydroxy. More preferably,  $R_1$  is phenyl- $C_{1-6}$ alkyl substituted on the phenyl by a straight or branched, preferably straight,  $C_{6-14}$ alkyl chain. The  $C_{6-14}$ alkyl chain may be in ortho, meta or para, preferably in para.

Preferably each of  $R_2$  to  $R_5$  is H.

A preferred compound of formula I is 2-amino-2-tetradecyl-1,3-propanediol. A particularly preferred S1P receptor agonist of formula I is FTY720, i.e. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form (referred to hereinafter as Compound A), e.g. the hydrochloride, as shown:



A preferred compound of formula II is the one wherein each of  $R'_2$  to  $R'_5$  is H and m is 4, i.e. 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound B), e.g. the hydrochloride.

A preferred compound of formula III is the one wherein W is  $\text{CH}_3$ , each of  $R''_1$  to  $R''_3$  is H,  $Z_2$  is ethylene, X is heptyloxy and Y is H, i.e. 2-amino-4-(4-heptyloxyphenyl)-2-methyl-butanol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound C), e.g. the hydrochloride. The R-enantiomer is particularly preferred.

A preferred compound of formula IVa is the FTY720-phosphate ( $R_{2a}$  is H,  $R_{3a}$  is OH,  $X_a$  is O,  $R_{1a}$  and  $R_{1b}$  are OH). A preferred compound of formula IVb is the Compound C-phosphate ( $R_{2a}$  is H,  $R_{3b}$  is OH,  $X_a$  is O,  $R_{1a}$  and  $R_{1b}$  are OH,  $Y_a$  is O and  $R_{4a}$  is heptyl). A preferred compound of formula V is Compound B-phosphate.

A preferred compound of formula V is phosphoric acid mono-[(R)-2-amino-2-methyl-4-(4-pentyloxy-phenyl)-butyl]ester.

A preferred compound of formula VIII is (2R)-2-amino-4-[3-(4-cyclohexyloxybutyl)-benzo[b]thien-6-yl]-2-methylbutan-1-ol.

When the compounds of formulae I to IX have one or more asymmetric centers in the molecule, the present invention is to be understood as embracing the various optical isomers, as well as racemates, diastereoisomers and mixtures thereof are embraced. Compounds of formula III or IVb, when the carbon atom bearing the amino group is asymmetric, have preferably the R-configuration at this carbon atom.

Examples of pharmaceutically acceptable salts of the compounds of the formulae I to IX include salts with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate and benzenesulfonate salts, or, when appropriate, salts with metals such as sodium, potassium, calcium and aluminium, salts with amines, such as triethylamine and salts with dibasic amino acids, such as lysine. The compounds and salts of the methods of the present invention encompass hydrate and solvate forms.

Compounds of formulae I to IX have, on the basis of observed activity, e.g. as described in EP-A1-627,406, been found to be useful e.g. as immunosuppressants, e.g. in the treatment of acute allograft rejection or autoimmune disorders.

Alzheimer disease is a progressive degenerative disease of the brain characterized by the insidious onset of dementia. Impairment of memory, judgment, attention span, and problem solving skills are followed by global loss of cognitive abilities. Accordingly, there is a need for agents which are effective in the treatment of such a disease and disorders. It has now been found that S1P receptor agonists have interesting properties which make them useful for treating progressive dementia and brain degeneration.

In accordance with the particular findings of the present invention, there is provided:

1.1 A method for treating progressive dementia or brain degeneration in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof.

1.2 A method for treating  $\beta$ -amyloid-related inflammatory diseases or disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof.

Examples of such diseases and disorders are e.g. Alzheimer disease, multiple myeloma, amyloidosis or cerebral atherosclerosis.

1.3 A method for reducing or inhibiting loss of cognitive abilities in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof.

2. A sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I, or a pharmaceutically acceptable salt thereof for use in the preparation of a pharmaceutical composition for use in any method as defined under 1.1 to 1.3 above.

3. A pharmaceutical composition for use in any method as defined under 1.1 to 1.3 above comprising a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable diluents or carriers therefor.

Utility of the sphingosine-1-phosphate (S1P) receptor agonists, e.g. a compound of formula I, in treating diseases as hereinabove specified, may be demonstrated in animal test methods as well as in clinic, for example in accordance with the methods hereinafter described.

A.1 Peripheral blood mononuclear cells are prepared from peripheral venous blood of healthy volunteers (anticoagulated with EDTA). After Lymphoprep<sup>R</sup> density gradient centrifugation, peripheral blood mononuclear cells are collected and washed three times with normal saline. Positive selection of monocytes is performed by adding MACS colloidal superparamagnetic microbeads conjugated with monoclonal anti-human CD14 antibodies to cooled, freshly prepared peripheral blood mononuclear cell preparations in MACS buffer (PBS with 5 mM EDTA and 0.5% bovine serum albumin) according to the manufacturer's instructions. Cells and microbeads are incubated for 15 min at 4-6°C. In the meantime the separation column is positioned in the MACS magnetic field and washed with MACS buffer at room temperature. The cells are washed with MACS buffer, resuspended, and loaded onto the top of the separation column. The eluent containing CD14 cells is withdrawn and after removal of the column from the magnet, trapped monocytes (CD14<sup>+</sup>) are eluted with the sixfold amount of cold MACS buffer, centrifuged, and resuspended in medium containing 0.5% BSA. By immunocytochemistry, preparations yield a purity of approximately 98%.

#### Chemotaxis assay

Leukocyte migration is measured using a modified 48-blindwell microchemotaxis chamber equipped with 5µm pore-sized nitrocellulose filters for monocyte chemotaxis. In some experiments cells are incubated for 20 min with GFX [500nM], staurosporine [10ng/mL], tyrphostin-23 [10 ng/mL], wortmannin [10 nM], cholera toxin [1 nM], DMS [20 pg/mL to 20 µg/mL] or pertussis toxin [1 nM]. For determination of Aβ's potency to affect monocyte chemotaxis toward fMLP, cells with Aβ [1 aM to 1 µM] are incubated for 20 min. After washing twice, 50µl of cell suspension [1x10<sup>6</sup> cells/mL] is put into the upper compartment of the chemotaxis chamber and cells are allowed to migrate for 90 min toward fMLP. After these migration periods the filters are dehydrated, fixed and stained with haematoxylin-eosin. Migration depth is quantified by microscopy, the distance from the surface of the filter to the leading front of three cells being measured. Data are expressed as "chemotaxis index", which is the ratio between the distance of directed and undirected migration.

Semiquantitative RT-PCR

Total RNA is isolated from  $8 \times 10^6$  cells by phenol-chloroform-isoamylalcohol extraction (RNAClean™; Hybaid-AGS, Ulm, Germany). Reverse transcriptase reaction is performed on 1 µg of RNA using random hexamers reverse transcriptase (Gibco BRL, Life Technologies, Vienna, Austria). 10 µL of the reverse transcriptase reaction mixture is then subjected to 35 cycles of PCR in a 50 µL reaction mixture containing 1 pmol of sense and anti-sense primer pairs in a Perkin-Elmer thermocycler: 95°C - 30 sec (denaturation), 53°C - 60 sec (annealing), 72°C - 30 sec (extension). Hot Start Taq polymerase is from Qiagen Inc. (Valencia, CA, USA). Primers (MWG Biotech, Ebersdorf, Germany) are designed to amplify about 400 bp coding sequences of the receptors. Primers are designed as follows: Sphingosine-1-phosphate receptor (S1PR) 1 sense: CTG TGA ACA ATG CAC TGG, anti-sense: CCT ACG TAC TCA ACA TAG CC. S1PR 3 sense: ATC TGC AGC TTC ATC GTC, anti-sense: AGA TTG AGG CAG TTC. S1PR 2 sense: ACC ACG CAC AGC ACA TAA TG, anti-sense: AAA CAG CAA GTT CCA CTC GG. S1PR 4 sense: TGA ACA TCA CGC TGA GTG, anti-sense: ATC ATC AGC ACC GTC TTC. S1PR 5 sense: GAA ATG CAG CCA AAG GTG, anti-sense: TT ATC ACC CAC AAG GTC CTT C. The PCR products are subjected to agarose gel analysis.

RESULTSAβ- and Aβ precursor protein-induced chemotaxis.

To confirm that Aβ induces monocyte chemotaxis and to investigate whether Aβ precursor protein (Aβ-PP) is able to act comparably, monocytes are allowed to migrate toward different concentrations of Aβ [10 nmol/L to 1 µmol/L] or Aβ-PP [10 nmol/L to 1 µmol/L] for 90 min. Directed migration of monocytes is measured using a modified 48-blindwell microchemotaxis chamber equipped with 5 µm pore-sized nitrocellulose filters for monocyte chemotaxis. Migration depth is quantified by microscopy, measuring the distance from the surface of the filter to the leading front of three cells. Data are expressed as "chemotaxis index", which is the ratio between the distance of directed and undirected migration. Mean distance of undirected migration was  $57 \pm 4.5$  µm. Results confirm that Aβ induces chemotaxis in human monocytes with a maximum response at 1 pmol/L. Aβ-PP induces chemotaxis in a concentration-dependent manner, with the maximal response also at 1 pM.

Inhibition of Aβ and Aβ -precursor protein-induced monocyte migration by neuropeptides.

To delineate whether monocyte attracting neuropeptides influence Aβ- and Aβ-PP-induced monocyte locomotion, cells are exposed to neuropeptides, e.g. bombesin, CGRP, SP, SN or

VIP and chemotaxis toward A $\beta$  and A $\beta$ -PP is tested as described above. All neuropeptides inhibit chemotaxis concentration-dependently.

#### Signaling enzyme inhibitors affect A $\beta$ -induced migration

Monocytes are incubated with several enzyme blockers. The protein kinase C inhibitor GFX, the tyrosine kinase inhibitor tyrphostin-23, and the phospholipase-3 inhibitor WTN are used first for blocking signaling enzymes; involvement of G proteins is then tested with PTX which is known to induce Gi proteins, and CTX which induces Gs proteins. After washing, chemotaxis experiments toward A $\beta$  (1 pmol/l) and A $\beta$ -PP (1 pmol/l) are performed. Data are expressed as chemotaxis index, which is the ratio between directed and random migration. Mean distance of random migration is  $54 \pm 3.2 \mu\text{m}$ .

Table 1

Treatment	Chemotaxis Index	
	A $\beta$ Mean (+/- SEM)	A $\beta$ -PP Mean (+/- SEM)
Medium	1.786 (0.078)	1.639 (0.076)
GFX (500 nmol/l)	1.143 (0.08)	1.098 (0.10)
IBMX (10 ng/ml)	1.234 (0.06)	1.208 (0.09)
Tyrphostin-23 (10 ng/ml)	1.435 (0.04)	1.398 (0.07)
WTN (10 nmol/l)	1.023 (0.05)	1.115 (0.08)
CTX (1 nmol/l)	1.768 (0.10)	1.790 (0.13)
PTX (1 nmol/l)	1.098 (0.08)	1.123 (0.06)

#### N,N-dimethylsphingosine inhibits A $\beta$ - and A $\beta$ -PP-induced monocyte migration

Human monocytes are pre-treated with the selective sphingosine kinase inhibitor, DMS, at different concentrations (e.g. 100 fmol/l to 100 nmol/l). fMLP is used as a control attractant. Treatment with DMS inhibits A $\beta$ - and A $\beta$ -PP-induced chemotaxis, whereas fMLP-induced chemotaxis is not affected.

#### S1P receptor agonist deactivates migration of human monocytes toward A $\beta$ and chemokines

Monocytes are incubated with DMS, Compound A or medium for 20 min. After washing, chemotaxis experiments toward A $\beta$  [1 pmol/L] are performed. Data are expressed as chemotaxis index, which is the ratio between directed and random migration. Mean distance of random migration is  $56 \pm 5.6 \mu\text{m}$ . DMS and a S1P receptor agonist alone inhibit the migration of the cells, whereas co-treatment with both restores the chemotactic effect of A $\beta$  and A $\beta$ -PP. Results with Compound A are as follows:



Table 2

	Chemotaxis
Treatment	Mean (+/- SEM)
Medium	1.825 (0.14)
DMS (2 ng/ml)	1.423 (0.18)
Compound A (2 ng/ml)	1.077 (0.18)

#### S1P receptor mRNA expression is regulated by A $\beta$

After pretreatment with Compound A at various concentrations [20 pg/mL to 20  $\mu$ g/mL] for 20 min, cells are washed and chemotaxis toward A $\beta$  and A $\beta$ -PP [1 pM] is tested as described above. Data are expressed as chemotaxis index, which is the ratio between directed and undirected migration of cells. After the incubation period, RT-PCR is performed and equal amounts of cDNA are subjected to agarose gel electrophoresis. Induction of S1PR 2 and S1PR 5 mRNA in A $\beta$ -treated cells is observed.

#### B. Clinical Trial

The trial is carried out employing groups comprising 6 to 10 subjects identified as exhibiting mild to moderate Alzheimer dementia in accordance with parameters defined in DSM-III (Diagnostic and Statistical Manual of Mental Disorders, 3rd edition) and excluding subjects exhibiting severe cardiovascular disease, hypotension, severe endocrine disease, severe liver disease, renal insufficiency. The trial commences with an EEG and psychometric test at time 0. Subjects then receive placebo, or test medication administered as described below, and the EEG and psychometric tests are repeated 60, 120 and 180 minutes subsequent to administration. Psychometric tests employed include:

- (i) The Selective Reminding Test / Buschke: "Selective Reminding for Analysis of Memory and Learning", J. Verbal Learning and Verbal Behaviour 12, 543-550 (1973);
- (ii) Measurement of Constructional Ability (Muratomo et al.: "Effect of Physostigmin on Constructional and Memory Tasks in Alzheimer's disease", Arch. Neurol. 36, 501-503 (1973); and
- (iii) Memory of Geometric Figures (Benton revised visual retention test).

During the course of the trial, subjects receive either a placebo or a S1P receptor agonist, e.g. Compound A, at dosages of from ca. 0.25 to ca. 10 mg/p.o. administered once or in divided dosages 2 or 3x.

The following additional parameters are monitored:

Haematology: R.B.C., HB, HCT, W.B.C, differential counts, sedimentation rate, blood

glucose.

Urine: Albumin, glucose.

Serum: Alkaline phosphatase, ALT, AST, S-GT, S-bilirubin, S-T4, S-T3, S-TSH, creatinin.

Subjects receiving a S1P receptor agonist, e.g. Compound A, in the above indicated dosages exhibit improved condition as evidenced by EEG results and the results of psychometric tests as compared with subjects receiving placebo.

Daily dosages required in practicing the method of the present invention when S1P receptor agonist is used will vary depending upon, for example, the compound used, the host, the mode of administration and the severity of the condition to be treated. A preferred daily dosage range is about from 0.1 to 100 mg as a single dose or in divided doses. Suitable daily dosages for patients are on the order of from e.g. 0.1 to 50 mg p.o. The S1P receptor agonist may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets, capsules, drink solutions, nasally, pulmonary (by inhalation) or parenterally, e.g. in the form of injectable solutions or suspensions. Suitable unit dosage forms for oral administration comprise from ca. 0.1 to 30 mg, usually 0.25 to 30 mg S1P receptor agonist, e.g. Compound A, together with one or more pharmaceutically acceptable diluents or carriers therefor.

The S1P receptor agonist may be administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions, or topically. Pharmaceutical compositions comprising a S1P receptor agonist, e.g. a compound of formula I may be manufactured in conventional manner, e.g. as described in EP-A1-627,406 or in EP-A1-1,002,792.

The S1P receptor agonists may be administered as the sole ingredient or together with other drugs, e.g. an AMPA receptor agonist or a nootropic.

The term "AMPA receptor antagonist" as used herein includes, but is not limited to an quinoxaline-dione aminoalkylphosphonate, e.g. as disclosed in WO 98/17672, or to further compounds such as EGIS 8332 (7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile), GYKI 47261 4-(7-chloro-2-methyl-4H-3,10,10a-triaza-benzo[f]azulen-9-yl)-phenylamine), irampanel (BIIR 561; N,N-dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine), KRP 199 (7-[4-[[[(4-carboxyphenyl)-amino]carbonyl]oxy]methyl]-1H-imidazol-1-yl]-3,4-dihydro-3-oxo-6-(trifluoromethyl)-2-quinoxalinecarboxylic acid), NS 1209 (2-[[[5-[4-

[(dimethylamino)-sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino[oxy]-4-hydroxybutanoic acid monosodium salt, e.g. prepared as described in WO 98/14447), topiramate (TOPAMAX, 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate, preparation, e.g. as described in US 535475) and talampanel (LY-300164, (R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzo-diazepine, preparation, e.g. as described in EP 492485), YM90K (6-imidazol-1-yl-7-nitro-1,4-dihydro-quinoxaline-2,3-dione), S-34730 (7-chloro-6-sulfamoyl-2-(1H)-quinolinone-3-phosphonic acid), Zonampanel (YM-872; (7-imidazol-1-yl-6-nitro-2,3-dioxo-3,4-dihydro-2H-quinoxalin-1-yl)-acetic acid), GYKI-52466 (4-(8-methyl-9H-1,3-dioxo-6,7-diaza-cyclohepta[f]inden-5-yl)-phenylamine), ZK-200775 (MPQX, (7-morpholin-4-yl-2,3-dioxo-6-trifluoromethyl-3,4-dihydro-2H-quinoxalin-1-ylmethyl)-phosphonic acid), CP-465022 (3-(2-chloro-phenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro-3H-quinazolin-4-one), SYM-2189 (4-(4-amino-phenyl)-6-methoxy-1-methyl-1H-phthalazine-2-carboxylic acid propylamide), SYM-2206 (8-(4-amino-phenyl)-5-methyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxylic acid propylamide, RPR-117824 ((4-oxo-2-phosphono-5,10-dihydro-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-9-yl)-acetic acid), LY-293558 (6-[2-(1H-tetrazol-5-yl)-ethyl]-decahydro-isoquinoline-3-carboxylic acid).

The term "nootropics" as used herein includes, but is not limited to nootropic plant extracts, calcium antagonists, cholinesterase inhibitors, dihydroergotoxin, nicergoline, piracetame, purine derivates, pyritinol, vincamine and vinpocetine. The term "nootropical plant extracts" as used herein includes, but is not limited to extracts from Ginkgo leafs. The term "calcium antagonists" as used herein includes, but is not limited to cinnarizine and nimodipine. The term "cholinesterase inhibitors" as used herein includes, but is not limited to donepezil hydrochloride, rivastigmine and galantamine hydrobromide. The term "purine derivates" as used herein includes, but is not limited to pentifyllin.

Extracts from Ginkgo leafs can be administered, e.g., in the form as marketed, e.g. under the trademark Ginkodilat™ according to the information provided by the package insert. Cinnarizine can be administered, e.g., in the form as marketed, e.g. under the trademark Cinnarizin forte-ratiopharm™. Nimodipine can be administered, e.g., in the form as marketed, e.g. under the trademark Nimotop™. Donepezil hydrochloride can be administered, e.g., in the form as marketed, e.g. under the trademark Aricept™. Rivastigmine can be prepared as disclosed in US 5,602,176. It can be administered, e.g., in the form as marketed, e.g. under the trademark Exelon™. Galantamine hydrobromide can

be administered, e.g., in the form as marketed, e.g. under the trademark Reminyl™. Dihydroergotoxin can be administered, e.g., in the form as marketed, e.g. under the trademark Hydergin™. Nicergoline can be administered, e.g., in the form as marketed, e.g. under the trademark Sermion™. Piracetam can be administered, e.g., in the form as marketed, e.g. under the trademark Cerebroforte™. Pentifyllin can be administered, e.g., in the form as marketed, e.g. under the trademark Cosaldon™. Pyritinol can be administered, e.g., in the form as marketed, e.g. under the trademark Encephabol™. Vinpocetin can be administered, e.g., in the form as marketed, e.g. under the trademark Cavinton™.

The structure of the active ingredients identified by code nos., generic or trade names mentioned herein may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active ingredients and, based on these references, likewise enabled to manufacture.

Where the S1P receptor agonists are administered in conjunction with other drugs, dosages of the co-administered compound will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition to be treated, and so forth. The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

In accordance with the foregoing the present invention provides in a yet further aspect:

5. A pharmaceutical combination comprising a) a first agent which is a S1P receptor agonist, e.g. a compound of formula I, e.g. Compound A, or a pharmaceutically acceptable salt thereof, and b) a co-agent, e.g. a second drug agent as defined above.
6. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a S1P receptor agonist, e.g. a compound of formula I, e.g. Compound A, or a pharmaceutically acceptable salt thereof, and a second drug substance, e.g. as indicated above.

S1P receptor agonists are well tolerated at dosages required for use in accordance with the present invention. For example, Compound A has an acute LD<sub>50</sub> > 10 mg/kg p.o. in rats and monkeys.

## CLAIMS

1. A method for treating progressive dementia or brain degeneration in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof, substantially as hereinbefore disclosed or defined.
2. A method for treating  $\beta$ -amyloid-related inflammatory diseases or disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof, substantially as hereinbefore disclosed or defined.
3. A method for reducing or inhibiting loss of cognitive abilities in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof, substantially as hereinbefore disclosed or defined.
4. A sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I, or a pharmaceutically acceptable salt, substantially as hereinbefore disclosed or defined, thereof for use in the preparation of a pharmaceutical composition for use in a method according to claim 1, 2 or 3.
5. A pharmaceutical composition for use in a method according to claim 1, 2 or 3 comprising a sphingosine-1-phosphate (S1P) receptor agonist, e.g. a compound of formula I or a pharmaceutically acceptable salt thereof, substantially as hereinbefore disclosed or defined, together with one or more pharmaceutically acceptable diluents or carriers therefor.
6. A pharmaceutical combination comprising a) a first agent which is a S1P receptor agonist, e.g. a compound of formula I, or a pharmaceutically acceptable salt thereof, substantially as hereinbefore disclosed or defined, and b) a co-agent, e.g. a second drug agent, e.g. substantially as hereinbefore disclosed or defined.
7. A method according to claim 1, 2 or 3 comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a S1P receptor agonist, e.g. a compound of formula I, substantially as hereinbefore disclosed or defined, or a pharmaceutically acceptable salt thereof, and a second drug substance, e.g. substantially as hereinbefore disclosed or defined.

8. A method, composition, combination or use according to any one of the preceding claims, wherein the S1P receptor agonist is 2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form.



PCT/EP2004/014436

